Tech Company Financing Transactions
Actinobac Biomed Funding Round
Actinobac Biomed closed a $100 thousand venture capital round on 2/21/2013. Investors included Foundation Venture Capital Group.
Transaction Overview
Company Name
Announced On
2/21/2013
Transaction Type
Venture Equity
Amount
$100,000
Round
Undisclosed
Investors
Foundation Venture Capital Group (George Heinrich)
Proceeds Purpose
The latest $100,000 investment will fund proof of concept studies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
15 Pelham Rd.
Kendall Park, NJ 08824
USA
Kendall Park, NJ 08824
USA
Phone
Website
Email Address
Overview
Actinobac is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Our drug candidates are based upon Leukothera® (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Benjamin Belinka
Chief Scientific Officer
Scott Kachlany
Browse more venture capital transactions:
Prev: 2/20/2013: Pinterest venture capital transaction
Next: 2/21/2013: Immunome venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs